Description
Release form
Tablets
Packing
30 pcs.
Pharmacological action
Cavinton – a drug that improves cerebral circulation, cerebral metabolism and rheological properties of blood.
Has a cerebroprotective effect. It reduces the severity of damaging cytotoxic reactions caused by stimulating amino acids and inhibits the functional activity of both transmembrane sodium and calcium channels, as well as NMDA and AMPA receptors. Potentiates the neuroprotective effect of adenosine. Stimulates brain metabolism, enhances the absorption and absorption of glucose and oxygen by the brain. Stimulates glucose transport through the BBB, shifts glucose metabolism to an energetically more beneficial aerobic direction. Selectively inhibits Ca2 + -calmodulin-dependent cGMP-phosphodiesterase, increases the concentration of cAMP and cGMP in the brain tissue, as well as the concentration of ATP and the ratio of ATP / AMP. It stimulates cerebral metabolism of norepinephrine and serotonin, stimulates the ascending norepinephrine system, and has an antioxidant effect.
The drug selectively enhances cerebral blood flow: increases the cerebral fraction of the minute volume decreases the resistance of the cerebral vessels, without affecting the parameters of the general blood circulation (blood pressure, minute volume, heart rate, heart rate).
Does not cause the robbery phenomenon, on the contrary, with its use, the blood supply to the ischemic, but still viable area with low perfusion increases, the phenomenon of reverse robbery.
Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it.
The drug improves microcirculation of the brain, inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.
Indications
In neurology – acute and chronic cerebrovascular insufficiency (transient ischemia, progressive stroke, post-stroke conditions, vascular dementia, cerebrovascular arteriosclerosis, post-traumatic and hypertensive encephalopathy, neuro-cerebrospinal neuropsychiatric insufficiency) (including memory impairment, dizziness, headache, aphasia, apraxia, motor disorders).
In ophthalmology – vascular eye diseases (atherosclerosis, angiospasm of the choroid and retina, degenerative diseases of the choroid, retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma).
In ENT practice – hearing loss (vascular, toxic or age-related), Meniere’s disease, cochleovestibular neuritis, tinnitus, dizziness (labyrinth origin), vasovegetative manifestations of menopause syndrome.
Contraindications
Pregnancy lactation severe forms of heart failure and cardiac arrhythmias hypersensitivity to vinpocetine or other components of the drug.
Special instructions
Cavinton does not have hepato- and nephrotoxic effects, therefore, when prescribing the drug to patients with liver and kidney diseases, correction of the dosage regimen is not required.
In case of lactose intolerance, it should be borne in mind that each tablet contains 83 mg of lactose.
Use in pediatrics
Do not recommend prescribing the drug to children under the age of 18 due to a lack of experience with Cavinton in this category of patients.
Dosage and administration
The course of treatment and dosage are determined by the attending physician.
In most cases, take 1 tablet (10 mg) 3 times a day.
Cavinton should be taken after a meal.
Course from 1 to 8 months, on average 3-4 months.
In case of drug withdrawal, the dose of Cavinton is reduced within 2-3 days.
Side effects
From the cardiovascular system: it is possible to intensify the manifestations of existing arrhythmias.
From the digestive system: nausea, heartburn, dry mouth.
From the central nervous system: headache, dizziness, sleep disturbance, weakness.
Allergic reactions: skin rash, urticaria.
Skin reactions: flushing of the skin.
Storage conditions
The drug should be stored in a dark place, out of the reach of children, at a temperature of 15 ° to 30 ° C.
Active ingredient
Vinpocetine
Terms and conditions
prescription
lekarstvennaja form
tablets
